logo

For the Inventor, By the Inventor

Tokyo, Japan

Teiichiro Koga

USPTO Granted Patents = 10

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 78(Granted Patents)


Location History:

  • Yokohama, JP (1998)
  • Tokyo, JP (1995 - 2000)

Company Filing History:

goldMedal10 out of 613 
 
Sankyo Company, Limited
 patents

Years Active: 1995-2000

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6040339 - Urea derivatives having ACAT inhibitory activity, their preparation and (2000-03-21),
2. 5880147 - Amide derivatives having ACAT inhibitory activity, their preparation and (1999-03-09),
3. 5843983 - Diphenylethane compounds containing a saturated heterocyclic group, (1998-12-01),
4. 5827855 - Hexahydronaphthalene ester derivatives their preparation and their (1998-10-27),
5. 5614550 - Amide and urea derivatives having anti-hypercholesteremic activity, (1997-03-25),
6. 5604256 - Octahydronaphthalene oxime derivatives for cholesterol biosynthesis (1997-02-18),
7. 5563169 - Tricyclic heterocyclic compound (1996-10-08),
8. 5534529 - Substituted aromatic amides and ureas derivatives having (1996-07-09),
9. 5491167 - Hexahydronaphthalene ester derivatives, their preparation and their (1996-02-13),
10. 5451688 - Hexahydronaphthalene ester derivatives, their preparation and their (1995-09-19),

Title: Teiichiro Koga: Innovator in Pharmaceutical Chemistry

Introduction

Teiichiro Koga, a prominent inventor based in Tokyo, Japan, has made significant contributions to pharmaceutical chemistry. With an impressive portfolio of ten patents, he has pioneered developments in compounds that exhibit valuable biochemical activity. His work primarily focuses on innovations related to acyl-CoA: cholesterol acyl transferase (ACAT) inhibitory activity.

Latest Patents

Koga's latest patents include groundbreaking advancements in urea and amide derivatives that inhibit ACAT activity. These compounds are characterized by complex chemical structures formulated to target specific biochemical pathways. His first notable patent details urea derivatives that possess ACAT inhibitory activity, while his subsequent innovation outlines amide derivatives with similar biochemical functions. Both patents emphasize the utility of these compounds in therapeutic applications, particularly in conditions relevant to cholesterol metabolism.

Career Highlights

Throughout his career, Teiichiro Koga has demonstrated a persistent commitment to research and innovation. Working at Sankyo Company, Limited, he has played a pivotal role in the development of pharmaceutical products aimed at tackling metabolic disorders. Koga’s scientific acumen has earned him recognition in the field, positioning him as a key contributor to advancements in medicinal chemistry.

Collaborations

Collaboration has been central to Koga's success, as he has partnered with esteemed colleagues such as Hiroshi Kogen and Sadao Ishihara. Together, they have fostered an environment of shared knowledge and innovation, leading to the development of numerous effective compounds. Their combined expertise has significantly enhanced the quality and impact of their research outcomes.

Conclusion

Teiichiro Koga exemplifies the spirit of innovation in the pharmaceutical industry, with a strong emphasis on chemistry that addresses critical health issues. His ten patents reflect a dedication to advancing medical science and improving patient outcomes. As he continues to explore new avenues in ACAT inhibition, the potential benefits of his work will likely resonate throughout the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…